Teva Pharmaceuticals

Teva Pharmaceuticals
Share

Teva Pharmaceuticals

 •  February 2

Teva seeking EU regulatory approval for anti-CGRP therapy for the prevention of migraine JERUSALEM--(BUSINESS WIRE)--Feb. 2, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for fremanezumab, an anti-calcitonin...

Teva Pharmaceuticals

 •  January 22

JERUSALEM--(BUSINESS WIRE)--Jan. 22, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that a Phase III registration study evaluating subcutaneously administered reslizumab (110 mg) in a pre-filled syringe did not meet its primary endpoint of significantly reducing the frequency of clinical asthma exacerbations...

Teva Pharmaceuticals

 •  January 15

JERUSALEM--(BUSINESS WIRE)--Jan. 15, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved the use of TRISENOX® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL)...

Teva Pharmaceuticals

 •  December 27, 2017

JERUSALEM--(BUSINESS WIRE)--Dec. 27, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the exclusive launch of a generic version of Reyataz®1 (atazanavir) capsules in the U.S. Atazanavir sulfate capsules are a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of...

Teva Pharmaceuticals

 •  December 15, 2017

JERUSALEM--(BUSINESS WIRE)--Dec. 15, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive launch of generic Viread®1 (tenofovir disoproxil fumarate) tablets 300 mg in the U.S. Tenofovir disoproxil fumarate tablets are a nucleotide analog HIV-1 reverse transcriptase inhibitor indicated in combination with...

Teva Pharmaceuticals

 •  November 29, 2017

Marks the first Phase III chronic migraine data to be published within anti-CGRP class JERUSALEM--(BUSINESS WIRE)--Nov. 29, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the publication of data from the pivotal Phase III HALO study evaluating the efficacy, safety and tolerability of two subcutaneous dose...

Teva Pharmaceuticals

 •  November 1, 2017

Teva receives $1.1 billion cash proceeds to progress repayment of term loan debt Closures mark first completion of planned divestiture of non-core assets to enable greater focus on core Specialty therapeutic areas of CNS and Respiratory JERUSALEM--(BUSINESS WIRE)--Nov. 1, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today...

Teva Pharmaceuticals

 •  October 4, 2017

JERUSALEM--(BUSINESS WIRE)--Oct. 4, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today commented that any launch by Mylan of a generic version of COPAXONE® 40mg/ml (glatiramer acetate) prior to final resolution of the pending patent appeals and other patent litigation should be considered an “at-risk” launch, which could...

Teva Pharmaceuticals

 •  September 25, 2017

JERUSALEM--(BUSINESS WIRE)--Sep. 25, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the reintroduction of the generic equivalent to Depo-Provera®1 Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 mg/mL, in the United States. Medroxyprogesterone acetate injectable suspension is a...

Teva Pharmaceuticals

 •  March 6, 2017

JERUSALEM--(BUSINESS WIRE)--Mar. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Cowen & Company 37th Annual Healthcare Conference in Boston, MA. When: Wednesday, March 8, 2017 at 9:20 AM ET Who: Marcelo Bigal, M.D. Ph.D., SVP, Head of Global Specialty Development, Mike Derkacz, SVP, Head...